Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
← catalyst calendarNCT06252649 · readout in 768 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
450estimated
Sites
291
Countries
Argentina, Australia, Austria +32
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-17 | actual | When the study began enrolling |
| Primary completion | 2028-09-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-04-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Colorectal Cancer
Interventions
- Drug: FOLFIRI Regimen
- Drug: Sotorasib — also filed as AMG 510, Lumakras, Lumykras
- Drug: Panitumumab — also filed as Vectibix
- Drug: Bevacizumab-awwb — also filed as MVASI
Primary outcome
what the primary-completion date above is the date OFPFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
measured Up to Approximately 3 Years
Publications
- PMID 39752885 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed